Mixed responses came from the European Medicines Agency’s (EMAs) reconsideration of banning hydroxyethyl starch (HES) solutions from the European market, with critics claiming the decision would be based on politics rather than scientific evidence. Despite support from a number of international societies and experts, and the EMAs PRAC recommending the proposed ban, the EMA made the decision to continue the marketing of HES under new restrictions, adding to the ongoing debate.
While the end of this debate doesn’t appear to be in sight just yet, you can learn more about the different intravenous fluids available, including albumin, gelatin, dextran, and crystalloid solutions, which may be more suitable in certain patient populations. As well as the most recent European Association for the Study of the Liver (EASL) clinical practice guidelines, you can also keep up to date with all of the latest evidence fuelling this debate in our series of publication digests.
Alternatively login via
Back to epgonline.org